In association with PharmaMar
PharmaMar is one of the few biopharmaceutical companies to have a product on the market, another awaiting commercialisation and various more at different stages of clinical development.
With more than 30 years of experience in marine bi
omedicine, they are the first company to carry out all the different phases of development of a drug of these characteristics and bring it to commercialisation. PharmaMar is an integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Thank
s to their “know how” and a solid and proven experience, today they are a global leader in their sector.
Since 2007, the Company’s compound therapy for soft tissue sarcoma and platinum sensitive ovarian cancer has become available in 80 countries; the first time an antitumour
al drug of a marine origin had been authorised.
An international company
PharmaMar is a biopharmaceutical company focused on oncology, with its head office in Madrid, Spain and a growing network of affiliates around the world. The internationalisation of the company is and has been a constant since their creation in 1986. From the start, they have understood that the access to knowledge around the world is fundamental to establish both scientific and commercial collaborations that would lead to both a solid and sustainable growth.
The process of expansion beyond Spanish borders started in 1999 with the opening of an office in the USA. Between 2012 and 2017, the necessary decisions to drive towards internationalisation were made; the Company wanting to maintain a direct presence in key countries to be able to continue with its growth. During this time offices have been opened in Italy, Germany, Switzerland, France, the United Kingdom, Belgium and Austria.
Committed with patients
PharmaMar currently has 232 qualified personnel working in Research and Development and Clinical Development functions. They are working on a rich pipeline focused on treating several diseases such as small-cell lung cancer, multiple myeloma, platinum-resistant ovarian cancer, breast cancer, endometrial cancer or angioimmunoblastic T-cell lymphoma with novel mechanisms of action.
Nowadays they have several studies ongoing in these diseases. The company already collaborates with many hospitals in the UK.
In advanced and relapsed small-cell lung cancer, their compound is under investigation in a phase III trial with 600 patients in 20 countries. This is an indication that has a poor prognosis and patients need therapeutic alternatives.
PharmaMar invests significantly in drug research and development. In 2016, the company’s financial position funded an increase in R&D expenditure by 30% when compared with 2015 to finance ongoing clinical research of the molecules at various stages of development.
PharmaMar´s future
Over the next five years, PharmaMar hopes to bring three molecules, across five different indications, to market; aiming to positively challenge the perception of what is possible in drug delivery, pioneer innovative new treatments and, above all, transform the lives of patients around the world.
